The scope and impact of treatment of latent tuberculosis infection in the United States and Canada
- PMID: 16424442
- DOI: 10.1164/rccm.200510-1563OC
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada
Abstract
Rationale: The scope of treatment of latent tuberculosis infection (LTBI) in the United States and Canada is unknown. Identifying the types of clinics that administer such treatment and patients who receive it could guide resource utilization and improve treatment initiation and completion.
Objectives: Estimate the number of persons started on LTBI treatment; describe the types of clinics that treat LTBI.
Methods: The Tuberculosis Epidemiologic Studies Consortium, consisting of 19 United States and 2 Canadian sites, conducted a survey among clinics that initiated LTBI treatment for>or=10 patients in 2002.
Results: Study catchment areas from the 19 United States sites represented 8.6% of the United States population and 12.7% of all tuberculosis cases in 2000. An estimated 37,857 patients started LTBI treatment during 2002 at 244 clinics surveyed. Of these treatment starts, 29,970 (79%) occurred at general public health clinics; immigrant/refugee clinics (2,409; 6.4%) and correctional/detention facilities (2,325; 6.1%) were the next most common sites. Based on these data, United States tuberculosis case rates, and United States population data, the estimated total number of LTBI treatment starts in the United States was 291,000-433,000. When the 37,145 persons who initiated LTBI treatment in the United States were extrapolated to the entire United States population, with a 5% lifetime risk of tuberculosis without treatment, and 20-60% treatment effectiveness, approximately 4,000-11,000 tuberculosis cases were prevented in the United States.
Conclusions: LTBI treatment is initiated among a substantial number of persons in the United States and Canada, primarily in the public sector. Treatment of LTBI can significantly decrease the tuberculosis burden.
Comment in
-
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada.Am J Respir Crit Care Med. 2006 Aug 15;174(4):480; author reply 481. doi: 10.1164/ajrccm.174.4.480. Am J Respir Crit Care Med. 2006. PMID: 16894021 No abstract available.
Similar articles
-
Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada.Int J Tuberc Lung Dis. 2013 Apr;17(4):473-9. doi: 10.5588/ijtld.12.0697. Int J Tuberc Lung Dis. 2013. PMID: 23485381
-
Predictors of failure to complete treatment for latent tuberculosis infection.J Infect. 2007 Mar;54(3):262-6. doi: 10.1016/j.jinf.2006.04.010. Epub 2006 Jun 12. J Infect. 2007. PMID: 16772095
-
Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000.Am J Respir Crit Care Med. 2008 Feb 1;177(3):348-55. doi: 10.1164/rccm.200701-057OC. Epub 2007 Nov 7. Am J Respir Crit Care Med. 2008. PMID: 17989346
-
Identification and management of latent tuberculosis infection.Am Fam Physician. 2009 May 15;79(10):879-86. Am Fam Physician. 2009. PMID: 19496388 Review.
-
Tuberculosis in humans and its epidemiology, diagnosis and treatment in the United States.Int J Tuberc Lung Dis. 2010 Oct;14(10):1226-32. Int J Tuberc Lung Dis. 2010. PMID: 20843412 Review.
Cited by
-
Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.J Infect. 2013 Nov;67(5):424-32. doi: 10.1016/j.jinf.2013.07.015. Epub 2013 Jul 8. J Infect. 2013. PMID: 23845828 Free PMC article.
-
Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis.Eur J Clin Microbiol Infect Dis. 2011 Jul;30(7):863-7. doi: 10.1007/s10096-011-1167-4. Epub 2011 Mar 24. Eur J Clin Microbiol Infect Dis. 2011. PMID: 21431989
-
Private sector tuberculosis prevention in the US: Characteristics associated with interferon-gamma release assay or tuberculin skin testing.PLoS One. 2018 Mar 28;13(3):e0193432. doi: 10.1371/journal.pone.0193432. eCollection 2018. PLoS One. 2018. PMID: 29590130 Free PMC article.
-
Estimates of Testing for Latent Tuberculosis Infection and Cost, United States, 2013.Public Health Rep. 2019 Sep/Oct;134(5):522-527. doi: 10.1177/0033354919862688. Epub 2019 Jul 24. Public Health Rep. 2019. PMID: 31339816 Free PMC article.
-
Potentially preventable tuberculosis among HIV-infected persons in the era of highly active antiretroviral treatment.Int J Tuberc Lung Dis. 2009 Mar;13(3):355-9. Int J Tuberc Lung Dis. 2009. PMID: 19275796 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical